Michael J. Fox Foundation
Michael J. Fox Foundation Launches Initiative to Support Development of LRRK2-Targeted Therapies
The LRRK2 Investigative Therapeutics Exchange aims to advance basic sciences and support development of new drugs and LRRK2-specific biomarkers.
The letter encourages drug developers to "further study and use" αSyn-SAA testing for selecting patients for clinical trials for Parkinson's and related diseases.
Foundation for the NIH Launches $21M Research Project to Identify Parkinson's Disease Biomarkers
The new public-private partnership is funded by organizations including the NIH, FDA, Michael J. Fox Foundation, C2N Diagnostics, and Sanofi.
The company recently published a study in JAMA on the test and is in the middle of two additional clinical trials as it closes a $6 million Series A funding round.
Global Parkinson's Genetics Program Signs up Psomagen for Large-Scale Whole-Genome Sequencing Study
Psomagen will sequence the genomes of approximately 80,000 individuals as part of a global effort to understand the genetic architecture of Parkinson's disease.